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Abstract
Some classical psychiatric disorders, such as schizophrenia, autism, major  depression, 
bipolar and obsessive‐compulsive disorders, have been related to neuroinflammatory pro‐
cess, immunological abnormalities, and neurotransmission impairment beyond genetic 
mutations. Neuroinflammation is mostly regulated by glial cells, which respond to physi‐
ological and pathological stimuli by anti‐ and pro‐inflammatory cytokine and chemokine 
signaling; moreover, recent studies have indicated that glial cells also respond to the neu‐
rotransmitters. Neurotransmitters regulate many biological processes, such as cell pro‐
liferation and synaptogenesis, which contribute to the formation of functional circuits. 
Alterations in the neurotransmission can lead to many pathological changes that occur in 
brain disorders. For example, studies have shown that neuroinflammation can alter the 
metabolism of glutamate as well as the function of its transporters, resulting in cognitive, 
behavioral, and psychiatric impairments. Cytokines as IL‐1β and IL‐6 appear to have an 
important influence in the dopaminergic and serotoninergic neurons. These data together 
suggest that glial cells via cytokines and abnormal regulation of neurotransmitters can 
influence psychiatric disorders. The present knowledge about this issue does not allow 
answering whether neuroinflammation is the cause or the consequence of neurotransmis‐
sion imbalance and emphasizes the importance to improve in vivo imaging methods and 
models to elucidate this enigma.
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1. Introduction
The processing and the transmission of information by the neurons depend on intracellu‐
lar and intercellular signaling, which occur, respectively, due to the conduction of an action 
potential and the neurotransmission across a synapse [1]. The action potential alters the 
membrane voltage and causes the opening of ion channels and, consequently, the entering 
of Ca2+ inside the neuron. This Ca2+influx leads to neurotransmitters release from the synaptic 
vesicle into the synaptic space where they can bind to their receptors and activate signal‐
ing cascades, be recaptured by presynaptic transporters and astrocytes, or be degraded by 
specific enzymes that are present in the synaptic space [2]. Neurotransmitters are molecules 
responsible for the transmission of information from one neuron (presynaptic) to another 
(postsynaptic) on chemical synapses. There are different kinds of neurotransmitters, which 
are classified according to their structure and function, and each one has its own mechanism 
of synthesis and action [2]. In this way, after being released in the synaptic space, they bind to 
their respective receptors and activate signaling cascades that will result in the clinical effects 
that are already well known. The neurotransmitters with greater clinical relevance are mainly 
the acetylcholine, norepinephrine (NE), glutamate (Glu), gamma‐amino butyric acid (GABA), 
dopamine and serotonin (5‐HT). Neuroinflammation refers to an inflammatory response that 
leads to accumulation of glial cells in the central nervous system (CNS) [3], and it is mainly 
constituted by CNS cells (neuron and glia) together with cytokines, pattern‐recognition recep‐
tors (PRRs), and peripheral immune cells [4]. The sustained neuroinflammation, for example, 
is capable of altering membrane expression of neurotransmitter receptors, glutamate and 
GABA and, consequently, impairing spatial learning, cognitive and motor functions by alter‐
ing neurotransmission [5]. Therefore, neuroinflammation seems to be involved in different 
neurodegenerative diseases [4] and psychiatric disorders including autism, schizophrenia, 
and major depression [6–8]. Also, as will be better explained ahead, altered neurotransmis‐
sion appears to be related to several neurological diseases such as autism spectrum disorders 
(ASD), obsessive‐compulsive disorder (OCD), bipolar disorder (BD), depression, and schizo‐
phrenia, which exhibit alterations of one or more neurotransmitters and either their absence 
or their excess may result in a pathological situation.
2. Microglia and neurotransmission alterations
Neurotransmission alterations are the etiological hypothesis for many neuropsychiatric 
diseases, and, in general, the hypotheses are based on the observations of agents that act‐
ing on the synaptic concentrations of neurotransmitters can improve the symptoms of the 
disease [9]. Actually, hypothesis previously postulated has been updated due to the finding 
of several studies. The monoamine hypothesis, for example, was the first one established to 
explain the symptoms of depression [9]. According to it, the reduction in the monoamine neu‐
rotransmitters, as serotonin and norepinephrine, is the main cause of the depressive symp‐
toms. However, based on more recent data, the etiology of depression can also be related 
to impairments in the amino neurotransmission, such as glutamate and GABA [9]. Another 
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example is the dopaminergic hypothesis about schizophrenia, which attributes the main 
cause of this disease to excessive stimulation of dopamine D2 receptors in the associative stri‐
atum and decreased stimulation of dopamine D1 receptors in prefrontal cortex [10]. Indeed, 
more recent studies have shown that the glutamate and its N‐methyl‐d‐aspartate (NMDA) 
receptor, as well the GABAergic, opioid, cholinergic, and serotonergic systems, seem also to 
be related with etiology of schizophrenia [10]. Alterations in the glutamatergic signaling were 
also already linked to ASD, a group of neurodevelopmental disorders characterized by neu‐
robehavioral and neurological dysfunctions [11]. Besides genetic propensity, inflammation 
is another factor that is involved with neurotransmission alterations, as well as neurodegen‐
erative and neuropsychiatric diseases [12, 13]. The acute inflammatory response has the goal 
to help the organism in the combat of pathogens and repair the damages caused by them. 
However, when this process remains persistent in time and becomes chronic, it generates a 
condition of cumulative damage, resulting in neuronal degeneration and in the development 
of a neurodegenerative disease [4]. According to studies, the use of anti‐inflammatory drugs 
was related to lower incidence of Alzheimer’s disease [3]. On the other hand, chronic inflam‐
matory processes such as cancer, infections, and autoimmune syndromes increase the risk of 
developing neuropsychiatric deviations [14].
For many years, it was assumed that cerebrum was an organ immunologically privileged 
owed to the existence of the blood‐brain barrier (BBB) (reviewed in [15]). However, a number 
of evidence suggests that peripheral inflammation could generate a brain inflammation by 
activating microglia and releasing some pro‐inflammatory cytokines, as interleukin (IL)‐6, 
IL‐1β, and tumor necrosis factor α (TNFα) [16]. The communication between immune sys‐
tem and brain occurs via cytokines and pathogen‐associated molecular patterns (PAMPs) that 
activate afferent nerves, such as the vagus nerve, or it could access the brain through regions 
that lack intact BBB, known as circumventricular organs (CVOs), thereby promoting activa‐
tion of microglia that secretes cytokines and chemokines, leading to the recruitment of cells, 
such as monocytes and lymphocytes to the brain [17, 18].
In the brain, resident macrophages are known as microglia and comprise approximately 15% 
of the cells of the CNS, being important in the regulation of inflammatory response, neuronal 
development, and maintenance of tissue homeostasis [19, 20]. These cells have receptors for 
serotonin, norepinephrine, GABA, acetylcholine, AMPA, and NMDA glutamate receptor, as 
well for group I, II, and III metabotropic glutamate receptors, variations in the concentrations 
of these mediators could interfere with microglial function and morphology, as well as in the 
recognition of neuronal activity by the microglia [21, 22]. Glutamate, an important excitatory 
neurotransmitter of the CNS, acts mostly in the hippocampus, cortex, and caudate nucleus 
through its metabotropic and ionotropic receptors, NMDA, AMPA, and Kainate and plays an 
important role in the processes of learning and memory formation, as well as in motor behav‐
ior and brain development [23]. The hyperglutamatergic hypothesis of autism is based on 
studies that showed high levels of glutamate in the serum, lower levels of the enzymes gluta‐
mate acid decarboxylase 65 and 67 (GAD65 and GAD67) [24, 25], and the presence of increased 
gliosis in these patients [11]. Moreover, studies in autism genome found genetic abnormalities 
in the gene GluR6, which is involved in brain development through the regulation of a mem‐
ber of the ionotropic receptor kainite family [26]. GABA is an important neurotransmitter 
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in inhibitory synaptic transmissions, which is synthesized from glutamate via the action of 
enzyme glutamic acid decarboxylase (GAD) [27]. Inflammation induced by lipopolysaccha‐
ride (LPS) and polyI:C during the gestational period reduces GABA‐ producing enzyme, GAD 
important for development of schizophrenia in animal models [28, 29]. In addition, TNF‐α 
leads to endocytosis of GABA receptors in rat hippocampus while IL‐1 and IL‐6 reduced 
GABAergic currents [30–32]. Beyond the decrease in the synaptic availability of monoamines, 
inflammatory cytokines upregulate the activity of the indoleamine 2,3‐dioxygenase (IDO) 
[14], which alters the neurotransmission by increasing catabolism of tryptophan, the precur‐
sor of serotonin, into kynurenine, which can be converted into the metabolite quinolinic acid 
by activated microglia [33]. Some neurodegenerative and neuropsychiatric disorders [34], as 
well mood and cognitive impairments [35], present high quantities of kynurenine and its 
neurotoxic metabolites in the brain or cerebrospinal fluid (CSF). More recently, it has also 
been shown to influence the neurogenesis in the human hippocampal [36]. Moreover, these 
cytokines are capable of decreasing the availability of tetrahydrobiopterin (BH4), which is a 
co‐factor to the production of all monoamines [37].
Despite the etiology of all of these neurodegenerative and neuropsychiatric disorders remain‐
ing unclear, growing and strong evidence supports the important roles of the neuroinflam‐
mation and the neurotransmission alterations in theses clinical situations. All these findings 
and new discoveries allow the improvement of the drug therapy and, consequently, the life of 
these patients, as well as contribute to the progress in the search for healing.
3. Inflammation: a key factor for mood disorders
Lately, the relationship between inflammation and mood disorders became more evident 
[38]. In fact, it seems that the immune dysregulation plays an important role in mood disor‐
ders during life and is also one of the main factors for the development of the disease. It has 
been shown that inflammation during prenatal or childhood can trigger the development of 
mood disorder [39]. A study showed that high levels of IL‐6 during childhood can be related 
to a higher risk of depression during adulthood [40]. The higher levels of IL‐6 and Il‐1β can 
be also an indicative of more susceptibility to commit suicide [41, 42]. Major depressive dis‐
order (MDD) and bipolar disorder (BD) have in common the presence of activated microglia, 
and hypothalamus‐pituitary‐adrenal (HPA) axis alterations are highly frequent as well as can 
modulate synapses and monoaminergic and glutamatergic systems [43].
4. Bipolar disorder (BD)
Bipolar disorder (BD) is a multisystem disorder characterized by depressive phases that alter‐
nate with mania or hypomania. However, the presence of some mixed episodes with those 
two phases is also a possibility. This disorder affects mood, cognition, behavior, and social 
functioning [44]. BD can be classified in BD‐I and BD‐II. BD‐I is a severe type of BD and 
the individual usually presents a manic episode for a week or more with an intense mood 
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 disturbance that needs hospitalization or psychotic features. BD‐II is classified if the individ‐
ual had a depressive and a hypomanic episode for at least 4 days with a change in functioning 
without a manic episode. The prevalence of BD is approximately 1% (BD I and BD II) [45]. 
This low rate can be explained by the fact that it is hard to diagnose hypomania. BD is also a 
disabling disease with a high mortality mainly because of comorbid medical conditions [46].
Inflammation is present in BD and is a good parameter to evaluate the prognosis of the impact 
on social and occupational life of patients and many other comorbidities are associated with 
higher rates of BD, such as autoimmune disorders, multiple sclerosis (MS), migraine, car‐
diovascular disorders, obesity, and diabetes which can reduce the life expectancy from 9 to 
20 years [47]. There is no consensus whether autoimmune diseases and psychiatric diseases 
have a common origin pathway; however, it is well known that patients with autoimmune 
diseases have more often psychiatric symptoms [48]. BD is associated with autoimmune dis‐
eases such as Guillain‐Barré syndrome (GBS), autoimmune hepatitis, rheumatoid arthritis, 
multiple sclerosis, systemic lupus erythematosus, psoriasis, and autoimmune thyroiditis [49].
A chronic low‐grade inflammation can disrupt the endothelial barrier permeability and lead 
to the exposure of bacteria and other compounds to the blood, which could be the first step 
to the development of autoantibodies that are also described in BD [50]. The presence of anti‐
NMDA receptor autoantibody has been found in blood and cerebrospinal fluids of patients, 
which has as main target GluN1 subunit. This autoantibody can impair the receptor dynam‐
ics and as a result, synapses can be disrupted, being capable to lead to mood disorders and 
to cognitive problems that are commonly related to these disorders [51]. During BD phases, 
pro‐inflammatory cytokines in serum can be elevated and levels can be different in each phase 
and serum cytokines can cross the blood‐brain barrier, subsequently causing neuroinflamma‐
tion [52, 53]. Although it is not yet known if there is causality between CNS and peripheral 
levels of pro‐inflammatory cytokines, the increased levels of these cytokines may be a conse‐
quence of rupture of CNS, loss of immune system integrity, and some unsolved inflammatory 
responses during the development [44].
In animal models, the deleterious effect of TNF‐α occurs via excess of glutamate that can cause 
LTP impairment [54] and the soluble TNF‐α receptor type 1 (sTNFR1) is more expressed in 
serum during euthymia, mania, and depressive episodes in comparison with healthy patients 
and becomes an important marker for BD [55]. Furthermore, inflammation can also modulate 
the neurotransmitter levels. For example, IL‐2, TNF‐α, and IL‐6 can decrease 5‐HT levels. IL‐2 
increases the cleavage of tryptophan by modulating indoleamine 2,3‐dioxygenase activity, 
which leads to a decrease in 5‐HT levels, while TNF‐α and IL‐6 increases the metabolization 
of 5‐HT to 5‐hydroxyindoleacetic acid (5‐HIAA) that also leads to low 5‐HT levels. The low 
availability of 5‐HT is also a main characteristic of BD and also MDD [43, 56].
Activated microglia also seems to present a very important feature in BD [57]. Serum TNF‐α 
and IL‐1β can overactivate microglial cells that increase apoptosis, oxidative stress and result 
in a neuronal dysfunction [58]. In postmortem brain of BD patients, the levels of IL‐1β, MyD88 
(key factor in TRL4 signaling), NF‐κB subunits (p65 and p50), and activation glial markers 
were elevated in the prefrontal cortex which is an important region for cognitive control 
and affective regulation [59]. Some structural brain changes such as the lateral ventricular 
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enlargement and functional changes in subgenual prefrontal cortex activity and mesolimbic 
connectivity were also found [60]. BD chronic inflammatory state also activates chronically 
hypothalamic‐pituitary‐adrenal (HPA) axis. BD peripheral cortisol levels are increased in 
patients during the mania/depression episodes and euthymia. Cortisol levels are an indicator 
of the severity of BD [61]. This increase in cortisol (hypercortisolemia) has also implications 
in weight gain, insulin resistance, and hypothyroidism [62]. In physiological conditions, the 
acute glucocorticoid receptor (GR) activation leads to anti‐inflammatory effect and in patho‐
logical conditions; the chronic activation has the opposite effect by preventing the negative 
feedback of the immune response which is caused by the modulation of GR. GR expression 
and sensitivity are decreased in hypothalamus and pituitary which maintain a pro‐inflamma‐
tory environment that trigger impaired neuroplasticity. All these changes lead to alterations 
in mood and cognition [63]. Childhood is a critical phase for the development of BD. In this 
period, the CNS and immune system are not entirely developed and this could be highly 
affected by psychological stress. Traumatic experiences in childhood increase the chances to 
develop BD and correlate with earlier onset and severity. It is also related to an inflammatory 
dysregulation that continues through adulthood which shows that an early trauma can have 
permanent consequences that could lead to a psychiatric disorder [64]. This intense psycho‐
logical stress could lead to impairments in GR signaling and in HPA hyperactivity which 
are associated with the lack of inflammation control [65]. Other factors in trauma also cause 
immune imbalance such as sleep disturbance, metabolic syndrome, gut microbiota leakage, 
and drug abuse [49, 66]. The susceptibility to the development of psychiatric disorder is also a 
result of genetic background together with priming events in early life [67, 68]. BD has a high 
rate of inheritance that could explain the differences between individuals against the same 
inflammatory stimulus. So far, the major histocompatibility complex (MHC) was identified in 
BD as highly polymorphic protein especially in the region of the HLA locus [69].
A correlation between TLR4 and TLR2 with BD has also been shown. Some genotypes of 
TLR4 and one specific genotype for TLR2 are an indicative of BD’s early onset and are asso‐
ciated with a poor inflammatory response. The impairment of important inflammatory 
response protein shows that inflammatory impairment is an important factor for BD and may 
somehow lead the individual to be more susceptible to other risk factors like infections and 
childhood traumas [70, 71]. Studies in BD patients showed that they have more alterations in 
genes related to IL‐6, IL‐8, and IFN pathway [72]. The gut microbiota can play an important 
role in BD because some prebiotics can increase the expression of BDNF and NMDA and 
also regulate immune system by decreasing hypersensitivity and better immune response 
[73]. BD patients usually do not practice physical exercises, which are a good tool to improve 
metabolic parameters that are important characteristics in BD and to have an antidepressant 
effect [74].
There is still a lot of debate concerning the role of immune dysfunction in the neuropsychi‐
atric disease. However, this immune dysfunction can be an important target in therapeutics 
and the control of immune system could have a relevant synergic effect during treatment. 
Many different studies showed the anti‐inflammatory concomitant antidepressants, mood 
stabilizers, and antipsychotics treatment could help the patients. On the other hand, other 
studies showed that some antipsycotics have pro‐inflammatory properties which could help 
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during the acute state [75]. Even though there is no consensus of the benefits of adjunctive 
therapy with anti‐inflammatory drugs. A study with TNF‐α inhibitors in BD patients without 
any antidepressant therapy showed only effect in patients with high levels of CRP and TNF‐α 
which shows how important is a more effective and individual treatment for BD in following 
the levels of different cytokines [76].
5. Major depressive disorder (MDD)
Major depressive disorder (MDD) is known as the most relevant disability cause world‐
wide and is one of the most frequent DSM‐IV disorder and the prevalence is of approxi‐
mately 17% [77]. MDD occurs more in women than in men and its etiology is multifactorial 
although MDD could be 35% heritable [78]. MDD is characterized by patients having major 
depressive episodes for at least 2 weeks. The episodes can be recurrent or isolated depend‐
ing on the intensity and number of symptoms. This could lead to a huge impact on occupa‐
tional and social life. The long‐lasting depressive episodes are followed by anxiety, feelings 
of guilt, and suicidal thoughts [79]. MDD has a similar profile to BD such as the increase of 
the risk to develop the disorder is higher if the individual had a trauma during childhood 
and this could also lead to an increase in the severity and in the lack of response to the 
 treatment [80].
Studies suggest that control of stress‐coping is impaired which can be a result of poor com‐
munication between a range of brain areas that are related to stress and emotions. It was also 
found that the volume of basal ganglia, hippocampus, and thalamus are smaller than healthy 
individuals [81]. In MDD patients, there is a hyper‐reactivity of amygdala not only during 
emotional process but also at resting state. Some important areas of control of amygdala in 
prefrontal cortex are not able to regulate hyperactivity in amygdala during a negative stimu‐
lus in MDD. This hyperactivity is related to a hyperexcitability and enhanced firing rate in 
stress‐response regions [82]. Thus, neurotransmitters regulation in the synaptic cleft plays an 
important role in MDD.
Monoamine hypothesis is an important mechanism involved in depression where there is a 
reduced activity of the catecholaminergic and/or serotoninergic systems [83]. The dopamine 
(DA) hypothesis considers the malfunctioning of the system of reward in mesolimbic system 
by the decrease of dopaminergic transmission that is the result of a decrease in the DA in the 
synaptic cleft that decreases the dopamine transporter expression and increases the D2 avail‐
ability in neurons membrane [84]. Noradrenaline (NA) hypothesis shows that noradrenergic 
neurons control important brain areas such as the medial orbitofrontal cortex that responds to 
positive stimuli and lateral prefrontal cortex, anterior cingulate, and anterior insula respond 
to negative stimulus. 5‐HT is important for the regulation of emotional behavior. It was pre‐
viously showed that the decrease of 5‐HT in synapse could impact negatively in mood of 
subjects which have MDD family history [85]. Therapeutic monoamine theory is supported 
because the drugs available can lead to DA, 5HT, and/or NA increase in synaptic cleft by 
blocking these monoamines reuptake. These monoamine transporters blockage help several 
patients; however, in more than 50% patients, they do not show any anti‐depressive effect and 
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also need 3–6 weeks to observe the changes in mood [86]. Although the monoamine theory 
is well established, it is understandable that this change in neurotransmitters can also lead to 
changes in other neurotransmitters, for instance, GABA, acetylcholine, histamine, and gluta‐
mate [87]. It has been also shown that the levels of glutamate in CSF and blood are increased 
in MDD patients compared to healthy controls. These higher glutamate levels can be reduced 
by the use of antidepressants. In postmortem studies, the elevated levels of glutamate in the 
brain and important alterations in the expression and function of NMDA receptor which is 
a relevant target for the treatment of MDD. Recently, ketamine, a NMDA inhibitor, could be 
a promisor treatment for the MDD. Thus, an impairment in glutamate pathway both in the 
neurotransmitter levels and in its receptor´s expression and function is present in MDD [88].
MDD patients presented elevation in serum levels of IL‐1β, IL‐6, and TNF‐α and an increased 
microglial activation in some regions of cortex and insula [75, 89]. Although the microglial 
activation is present, there is also important loss of glia in prefrontal cortex (PFC) and also 
that chronic stress may lead to MDD by impairing PFC’s astrocytes [90]. Almost all the impor‐
tant features observed in BD are also found in MDD, for example, the leaky gut is also seen 
in MDD which has higher concentrations of IgM and IgA and the presence of high levels 
of C‐reactive protein [91]. MDD is related to neurodegenerative diseases especially because 
of the presence of neuroinflammation, a common factor between all neurodegenerative dis‐
eases. There is a higher probability of Alzheimer’s disease (AD) patients developing MDD 
and vice‐versa. Since increased pro‐inflammatory cytokines in CSF can lead to depression 
in AD patients, elevated levels of IL‐10 are associated with lower depression scores, show‐
ing the relevance of inflammation in the severity of MDD. The Aβ40/Aβ42 ratio in serum 
was increased in MDD patients in comparison with healthy controls which show that the 
Aβ cleavage control is also impaired. MDD and AD are associated with impaired signaling 
pathways involving the decrease of BDNF expression, an important growth factor in CNS, 
and changes in the volume of regions in the brain related to limbic system. However, the exact 
mechanism involving MDD and AD is still unknown [92–94].
Parkinson’s disease (PD) patients present impairment in monoaminergic systems (dopamine, 
serotonin, and noradrenaline) which can lead to MDD. However, the glutamatergic system 
is also impaired in PD which could also lead to MDD and cognitive deficits that is also fre‐
quently related to MDD [95]. There is also strong evidence suggesting MDD being associated 
with Huntington’s disease (HD), maybe because of high rates of suicide in HD patients com‐
pared to the population in general, and that the HD patients can develop MDD during the 
disease course [96]. Amyotrophic lateral sclerosis as all other neurodegenerative diseases has 
also an association with MDD. The ALS progression occurs faster if the patients have a high 
depressive score [97].
Aging can also be an important factor for MDD, because older adults are more vulnerable to 
MDD. During aging process, there is a reduction in some neurotransmitters such as dopa‐
mine and noradrenaline, decrease of BDNF expression, and also increased levels of cortisol 
due to the imbalance of HPA axis [98]. There is also the involvement of glial activation and 
expression of pro‐inflammatory cytokines that affect the synaptic activity and also are found 
in MDD patients [99].
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6. Obsessive‐compulsive disorder
Obsessive‐compulsive disorder (OCD) is an anxiety disorder with a prevalence of 2.3% and 
does not present any correlation between gender [100]. This disorder is characterized by 
recurrent intrusive thoughts or images that become obsessions and cause a huge distress that 
lead the individuals to present repetitive behaviors or mental ritual. In OCD, there is an over‐
lap between cortico‐striato‐thalamic circuits [76]. The repetitive behavior is maybe due to a 
communication disruption between cortex and dorsal striatum. Studies suggested that the 
reward system and processing emotional stimuli are impaired in OCD. Thus, the emotional 
states are dysregulated and the proportion of response is also lost [101]. The precise cause 
of OCD onset is still not revealed and this disorder can appear during childhood or adult‐
hood. OCD share some features with MDD and BD such as autoimmunity, genetic factors 
and the comorbid diseases; however some different comorbidities are specific for OCD, such 
as Tourette’s syndrome and eating disorders [102]. The role of microglia in OCD has not been 
completely elucidated. However, an OCD mouse model called Hoxb8 KO seems to present 
microglial impairment, but new studies in patients should appear to contribute with this idea. 
This possible mechanism could be a result of dysregulation of glutamatergic system [103]. 
OCD has been also related to streptococcal infections in early life [104]. Pro‐inflammatory 
cytokines IL‐6, IL‐2, IL‐4, and TNF‐α are increased in plasma of OCD subjects suggesting an 
important role of inflammation also in OCD [105].
7. Schizophrenia
Schizophrenia comprises a group of closely related chronic psychotic disorders that are char‐
acterized by a particular type of disordered thinking, behavior, and in affectionate relation‐
ships. The most common abnormalities are a special disorder in the perception of one’s self 
in relation to the external world and hallucinations that differ from delirium and other con‐
fusional states, sometimes observed in dementia and depression [106]. Before the onset of 
schizophrenic disease that usually happens in the end of the childhood or early adulthood 
or when in remission, the individuals can be considered normal except by their vague and 
concerned appearance with their own thoughts. There is also a difficulty to fully understand 
figurative statements or to discern irrelevant to relevant data, to respect the logical limit 
of time and space and opposite things can be considered as identical as conceptual rela‐
tionships are distorted. Schizophrenic patients are usually unable to clearly communicate 
an idea. All these symptoms can be categorized as cognitive symptoms because it directly 
reflects in executive functions including inability to sustain attention and working memory 
impairment [57]. Such confused thoughts reflect in the patient’s behavior that can manifest 
as social withdrawal, idleness, aimlessness, aloof, and self‐absorption. These are referred to 
as negative symptoms. Finally, schizophrenic patients can also present auditory and visual 
hallucinations, bizarre actions, aggression, agitation, delusion, paranoia, and major thought 
disorders that are symptoms categorized as positive. Cognitive and negative symptoms 
seem to precede positive symptoms, however, although their distinct clinical manifestations, 
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it is possible that they usually can co‐exist. The prevalence of this syndrome worldwide is 
about 0.5–1.0% and seems to be related to industrialization, urbanization, and increasing 
population density [107, 108].
In vivo imaging studies suggest common macroscopic brain abnormalities associated with 
schizophrenia, also present in drug‐naïve patients with first episode psychosis, that include 
ventricular enlargement, decreased cortical and hippocampal volume, and reduced neuronal 
size. Furthermore, functional neuroimaging in patients with schizophrenia detected aberrant 
activity of neuronal circuits in prefrontal cortex, hippocampus, and also some subcortical 
structures [109]. In accordance with these findings, there was observed a decrease in NMDA 
receptor expression in postmortem analysis of prefrontal cortex of schizophrenic patients 
[110], and, in addition, preclinical and clinical data support the theory of stage‐specific gluta‐
matergic abnormalities in this illness because analysis of in vivo proton magnetic resonance 
spectroscopy (1H‐MRS) to measure glutamine concentrations in the brain of schizophrenic 
patients compared to control subjects suggests that early‐stage schizophrenia appeared to be 
associated with abundant glutamatergic activity whereas late‐stage schizophrenia showed 
decreased glutamatergic activity [111].
Furthermore, growing evidence suggests a myelination dysfunction and altered oligoden‐
drocyte number, as well as myelin, N‐acetylaspartate (NAA), and fatty‐acid biosynthesis dys‐
function in prefrontal cortex of postmortem schizophrenia patients, possibly as a mechanism 
underlying the observed reductions in white mater volume. NAA can also be considered a 
function neuronal marker because it acts as an osmolyte and donate its acetate group in myelin 
synthesis [112]. Other metabolites were also analyzed, in vivo, by fractional anisotrophy (FA), 
as myo‐inositol, that is associated with aging and neuroinflammation. This metabolite is 
highly expressed in astrocytes and is also a precursor for the cell signaling phosphatidylino‐
sitol and for synthesis phospholipids in cellular membrane. During chronic inflammation 
and/or slow virus infections of the brain, during glial activation and macrophage infiltra‐
tion, an increase in myo‐inositol is observed. Indeed, myo‐inositol increase may contribute to 
hypomyelination disorders associated with inflammation on white matter microstructure in 
general [113].
The immune system can contribute to the pathogenic process by generating reactive nitro‐
gen and oxygen species, releasing cytokines via microglia and lymphocytes that promote 
neuroinflammation. Specifically, the heme oxygenase (HO) system that acts as a sensor for 
oxidative stress as well as a key modulator of redox homeostasis is composed by two major 
isoforms, the heme oxygenase 1 (HO‐1) that is inducible and the heme oxygenase 2 (HO‐2) 
that is constitutive. Recently, there are some lines of evidence suggesting the involvement of 
HO‐1 in the pathogenesis of schizophrenia [114]. Furthermore, sustained increase of HO‐1 
in the brain during the pre‐ or perinatal period could lead to activation of HO‐1 in astro‐
cytes prior to the maturation of offspring mesolimbic and nigrostriatal system, what induces 
changes in DA network structure and function predisposing to neurodevelopmental pheno‐
types of schizophrenia observed in early adulthood [114]. In the adult, one of the most impor‐
tant and well‐established disturbances recognized in schizophrenia is in the dopaminergic 
neurotransmission, therefore the actual antipsychotics classified as typical and atypical that 
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are effective in schizophrenic positive symptoms are antidopaminergic drugs, that are not 
effective on cognitive, negative, and other deficits found in schizophrenic patients [115]. The 
dopaminergic dysfunction can be a consequence of glutamatergic hypofunction in schizo‐
phrenia, being glutamatergic system closely related to the immune system [115].
Some in vitro studies proposed that after antipsychotics therapy, some cytokine levels become 
normalized, such as IFN‐γ, that is blunted in the illness, as well as IL‐2, ICAM‐1, and the 
ICAM‐1 ligand leukocyte function antigen‐1, TNF‐α, and TNF‐α receptors (for more details 
[119]). Furthermore, medicated schizophrenics patients presented an increase in IL‐18 serum 
levels that play a pivotal role in immunological response type‐1 and a decrease in IL‐6, one 
important cytokine of type‐2 immune response, suggesting a role for antipsychotics in cyto‐
kine levels balance [119]. In schizophrenic patient’s blood sample, it is possible to observe the 
predominance of type‐2 immune response due to activated monocytes releasing IL‐6, high 
levels of Th2 type lymphocytes, immunoglobulin E and IL‐10 serum levels. In CSF of juve‐
nile schizophrenic patients it was observed an increase in IL‐4 levels, one of the most impor‐
tant cytokines in type‐2 response indicating that this predominance is not only an exclusive 
peripheral immune response phenomenon [115].
Science is still far from an effective answer and treatment to offer to schizophrenic patients 
and, therefore, is still hurried to consider the pro‐inflammatory cytokines as a possible tar‐
get to psychosis treatment. There are many preclinical trials being performed in the world 
focusing on schizophrenia and major depression treatment with monoclonal antibodies to 
anti‐ and pro‐inflammatory cytokine (infliximab, tocilizumab) [116], but the Janus face of 
inflammation mechanisms still needs to be carefully and detailed understood especially in 
the psychotic brain.
8. Autism spectrum disorders (ASDs)
Disorders on the autism spectrum are classified as neurodevelopmental disorders including 
childhood disintegrative syndrome, autism itself, pervasive developmental disorder not‐oth‐
erwise specified (PDD‐NOS) and Asperger syndrome, Rett’s syndrome [11]. Autism itself is 
a debilitating neurodevelopmental disorder that starts at early childhood with genetic and 
environmental causes and immune influence. The ASD symptoms comprise impaired lan‐
guage and communication, impaired social relationship, repetitive behaviors, and a narrow 
range of interests and many autistics also have intellectual disability [117]. Intellectual dis‐
ability (ID) comprises significant limitations in both intellectual functioning and adaptive 
behavior starting in childhood. The stable incidence of ASD in children has been estimated in 
0.5–1.0% B [117, 11].
In the brain, neuropathologic alterations observed in ASD correlates to cytoarchitecture 
abnormalities that affect many structures as cortex, limbic system, and cerebellum, leading to 
hypoplasia of the inferior vermis of the cerebellum with loss of Purkinje cells, asymmetrical 
enlargement of the amygdala, and increased gliosis (GFAP), whereas biochemical abnormali‐
ties include altered energy metabolism, dysregulated amino acid metabolism with increased 
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aspartate and glutamate serum levels in the amygdala and hippocampus [117]. It is well 
known that in ASD pathology, abnormalities in genes that regulate the expression of glutama‐
tergic receptors are involved, as mutations in chromosome 6q21, where GluR6 gene is located 
[26]. The GluR6 genes codify the family of kainite receptors that are ionotropic glutamatergic 
receptors very important during development [117].
The degree of ASD severity appears to be related to the intensity and period that excitotoxic 
or immune insult occurs. Woman exposed to ethanol during pregnancy, as well as ketamine, 
phencyclidine, benzodiazepines, barbiturates, anticonvulsants, or anesthetics can have 
GluR activity altered. During development, CNS neurons are more susceptible to synaptic 
environment, and disturbances that increase NMDA receptors activity can easily trigger 
neurodegeneration due to excitotoxicity [11]. During development of the neural systems, 
an excess of extraneural glutamate can alter the migratory neuronal pattern, differentia‐
tion, and synaptic development, leading to different abnormal brain architecture degrees. A 
postnatal injury seems to produce lesser ASD syndromes compared to prenatal, as human 
brain continues to develop during the first 2 years of childhood. In older children, injury 
due to elevated levels of heavy metals, glutamate, and inflammatory cytokines secondary 
to microglial activation can affect postnatal brain development [11]. Based on observations 
made from adult brain exposed to elevated inflammatory cytokines, the capacity of immune 
system to reestablish a homeostatic state is the major determinant factor as abnormalities 
of immune system function is always reported in ASD, being overactivation the most com‐
monly seen [11].
According to the literature, immunological abnormalities reported in ASD include a shift in 
T‐helper cells,Th1/Th2, balance, abnormal reactivity of lymphocytes, increased levels of cyto‐
kines as IL‐1β and TNF‐α, and finally elevated levels of anti‐brain antibodies, specifically anti‐
bodies against neurotransmitter receptors. In the autistic brain, a considerable loss of Purkinje 
cells is observed in the cerebellum, the most damaged area, followed by glial activation wide‐
spread all over the brain. There is also an increase in macrophage IL‐6 and chemoattractant 
protein‐1, which play an important role in the response of innate immune system including 
monocytes and T‐cell activation [11].
Therewithal, there are considerable data proposing that prolonged and excessive microglial 
activation can impair either neurodevelopment or neurogenesis due to the increase in cyto‐
kine release by microglia and excitotoxicity as already observed in CSF, brain tissue, and 
blood of autistic child with high levels of cytokines and glutamate [118]. The co‐localization 
of NMDA receptors with TNFR was also reported, implicating that GluR can interact with 
inflammatory cytokine membrane receptors allowing a cross talk that can lead to excitotoxic‐
ity especially through TNFR1. Furthermore, TNF can increase the glial release of glutamate 
by upregulating glutaminase [119].
As in schizophrenia, elevated cytokines during pregnancy have a very important role in ASD 
as proposed by human studies that found increased levels of INF‐γ, IL‐4, IL‐5, and MCP‐1 
in mid‐gestational mother sera and IL‐4 and TNF in amniotic fluid [120]. Elevated levels of 
inflammatory chemokines such as granulocyte macrophage colony‐stimulating factor (GM‐
CSF) and cytokines as TNF, INF‐γ, IL‐1β, IL‐4, and IL‐6 during mid‐gestation have been more 
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related to ASD subphenotype that presents intellectual disability (ID) than to ASD alone or 
developmental delay (DD) without autism [121].
Moreover, the production of maternal autoantibodies reactive to seven developmentally regu‐
lated proteins in the fetal brain has only been measured in blood of women whose children were 
later diagnosed with ASD. The seven proteins are Y‐box binding protein 1 (YBX1), stress‐induced 
phosphoprotein‐1 (STIP1), lactate dehydrogenase A and B (LDH‐A and LDH‐B), cypin, and col‐
lapsing response mediator proteins 1 and 2 (CRMP1 and CRMP2) [120]. However, in order to 
determine the predictive value of the maternal autoantibodies for autism risk and diagnose, addi‐
tional studies need to be done, because at this moment it seems to influence, if not define, ASD.
During postnatal period, individuals with ASD could present an increase in endogenous circu‐
lating anti‐brain auto‐immunoglobulins correlating with aberrant behaviors, impaired develop‐
ment and with immune dysregulation (increased IL‐6, IL‐8, and MCP‐1) leading to an increase 
in the pro‐inflammatory Th1/Th2 ratio. Besides the observed increased baseline activity of 
(natural killer) NK cells, there is a decrease in response to activation suggesting dysfunctional 
activity and a shift in T‐cell population that is decreased [120]. However, the role of IL‐17 is still 
obscure in ASD despite some temptations of explanation in rodent maternal immune activation 
(MIA) models [122]. The relationship between autoimmune diseases and ASD has long been 
described. Autism has itself been considered an autoimmune disorder [123, 124] due to the find‐
ings that family history of autoimmune disorders is a risk factor for autism and autoantibodies 
can also be found in multiple sclerosis, systemic lupus erythematosus (SLE), and schizophrenia. 
These autoantibodies can also cross‐react with N‐methyl‐d‐aspartate receptors [124].
9. Schizophrenia and autism spectrum disorders (ASDs), a common 
source: neurodevelopmental hypothesis of maternal immune activation
There are many evidences linking the etiology and pathophysiology of schizophrenia, with 
immunological changes especially during prenatal lifetime. During pregnancy, MIA that can 
be triggered by many common viruses seems to be enough to cause offspring brain func‐
tion lifelong changes and behavior, in both animal models and humans [125, 126]. In 1964, 
after rubella pandemic, the incidence of two neurodevelopmental disorders, autism and 
schizophrenia, increased abruptly from less than 1% to about 13 and 20%, respectively [127]. 
Subsequent to this first observation, other studies revealed an association with outbreaks of 
influenza, chicken pox, polio and mumps, and schizophrenia or autism [120, 128, 129] as 
well as bacterial infections and parasite such as Toxoplasma gondii [125, 127]. Furthermore, 
any environmental insult or genetic predisposition that elevates immune responses above a 
threshold, like allergies, acute stress, asthma, and exposure to environmental pollutants, have 
been related to enhanced risk of schizophrenia and autism [125, 126].
According to this theory, during pregnancy, a maternal infection due to viral or bacterial 
invasion leads to pathogen recognition by peripheral immune cell through the action of the 
family of toll‐like receptors (TLRs), classified as pattern‐recognition receptors that is respon‐
sible, in peripheral immune system, for the generation and fast release of inflammatory 
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cytokines, among others. The cytokines can cross the placenta barrier arriving in the fetal 
blood circulation according to the cytokine structure, gestational stage, and the physiologi‐
cal conditions of both mother and fetus [107]. The placenta from vertebrates is a very com‐
plex organ that plays the important role of fetus protection from pathogenic invasion and 
maintenance of a normal development hormonal environment. In physiological conditions, 
cytokines are constitutively expressed in placenta and seem to play important roles in the 
healthy environmental maintenance [130]. The expression of toll‐like receptors (TLR) type 
2 and 4 on normal human chorionic villi of placenta suggests that placenta can constitute 
an immunological barrier prepared to sustain and respond a pathogenic attack being also 
considered a pregnancy‐specific component of the innate immune system. However, during 
maternal infection, a dangerous increase in environmental pro‐inflammatory cytokines can 
strike an increase in placental cytokines that can become threat to the normal development of 
fetal brain [130]. During the CNS development, different classes of cytokines have different 
important roles. In the normal development of dopaminergic phenotype, IL‐1β is the cytokine 
that can induce the mesencephalic progenitor cells conversion, whereas in embryonic hippo‐
campal neural stem cells (NSCs) this cytokine can exert anti‐proliferation, anti‐neurogenesis, 
and pro‐ gliogenesis effects. Furthermore, IL‐6 can modulate serotoninergic neurons viability, 
decreasing its survival in fetal brain, in an in vitro model of serotoninergic neurons from the 
rostral raphe embryonic cell culture. During development, TNF‐α, in turn, can not only act 
as a neurotrophic factor in dopaminergic ventral mesencephalic neurons but also it can be 
neurotoxic at the beginning of brain development [126].
Due to the dificulty of clinical research in identify the molecular pathways downstream of mater‐
nal infection, animal models of research became a valuable tool once through this model it become 
clear the critical roles of cytokines in this process together with oxidative stress, zinc deficiency 
and hypoferremia, mediating in prenatal lifetime the neurodevelopmental effects of infection 
[106, 126]. In animal models, pregnant rodents and non‐human primate (NHP) can be exposed to 
immunological manipulation, and brain structures of offspring can easily be compared to control 
offspring [131]. The behavior of the offspring can manifest a broad range of schizophrenia and 
autism‐related abnormalities and also decreased ability of the brain to filter out extraneous infor‐
mation, deficits in cognitive flexibility, working memory, and increased anxiety behavior [125, 
127, 131]. There are two different protocols that are very well established in MIA models, one 
that consists in pregnant female exposure to LPS, a bacterial endotoxin (lipopolysaccharide) and 
other that is based in exposure to polyriboinosinic‐polyribocytidilic acid (polyI:C), a synthetic 
analog of viral double‐stranded RNA. Both of them are recognized by toll‐like receptors (TLRs), 
a class of receptors that recognize pathogen, being LPS recognized by TLR4 and polyI:C by TLR3. 
The female exposure to LPS or polyI:C during pregnancy notably enhances pro‐inflammatory 
cytokine levels in many gestational structures as amniotic fluid and placenta and latter in fetal 
brain, leading to fetal microglia activation and an increase in transcription factor nuclear factor‐
кB (NF‐кB) activity in both fetal and neonatal brains [106, 132] at the same time as white matter 
injury is observed by evident hypomyelination together with  precursor cells of oligodendrocytes 
death and increased rate of apoptotic neurons during fetal and neonatal brain development. The 
activation of microglia together with this entire pro‐inflammatory scenario is sufficient to induce 
a delayed increase of AMPA receptor expression and activity in excitatory  synapses [132].
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When pregnant rodents are exposed to a model of viral infection with poly(I:C) injection, 
offspring tend to manifest autism spectrum disease behavioral symptoms, as abnormal 
communication, social interaction, and an increase in repetitive behaviors [126, 131]. When 
offspring reach adulthood they also exhibit other neuropathologies associated to schizo‐
phrenia, as reduced hippocampal volume and cortical thickness as well as and increased 
ventricular size, deficits in synaptic protein levels, in dendritic spine density, in long‐term 
plasticity and cortical malformation [122, 129], and associated to ASD, aberrant Purkinje 
cells [125, 127, 129]. Altered serotoninergic and dopaminergic signaling was also observed 
additionally to specific changes in inhibitory neurotransmission and a decrease in several 
components of the γ‐aminobutyric acid (GABA) system, related to both schizophrenia and 
ASD [125, 126, 129, 131]. Transposed to humans, it seems that most of maternal infections 
do not lead to ASD or schizophrenia in offspring, but it can act as a disease primer making 
individual more susceptible to the effects of this maternal infection in the presence of more 
than one risk factor along adult life, such as familiar historic of schizophrenia or autoim‐
mune diseases [125–127].
Notwithstanding, to bridge the gap between humans and rodents, several groups have estab‐
lished rhesus macaque in MIA models to validate remarkably strong finding in rodents. As 
rodents and humans, these models display behavior symptoms of schizophrenia and ASD 
that increase in intensity along with age, as repetitive behavior, abnormal communication, 
and impaired social interactions [129, 131]. Gray and white matter volume is also altered in 
MIA non‐human primate (NHP) models as well as changes in dendritic branching in neonatal 
offspring [129].
There are some theories made from animal observation suggesting that IL‐6 can cross the 
rodent placental barrier in early and middle gestation but not in the late. It was observed that 
a maternal viral‐like immune activation during the first half of mouse gestation could elevate 
IL‐6 protein levels not followed by an increase in endogenous interleukin production in fetal 
brain [133] suggesting that IL‐6, opposite to IL‐1β and TNFα, can easily cross the placental 
barrier also in humans. As a matter of fact, to develop and establish a functional immune 
system, a series of very well‐coordinated events during fetal development, that only in late 
gestational and postnatal stages will achieve the highest functional maturation period, seems 
to be necessary. In summary, the fetal cytokine reaction observed due to maternal infection 
is absolutely dependent on the precise gestational stage [107]. However, the mechanism by 
which this cytokines alter brain development is still unknown. There is an assumption that 
these cytokines can regulate the expression of immune molecules expressed in neurons, as 
histocompatibility complex I (MHCI) where it negatively regulates synapse formation, and 
the synaptic plasticity required for activity‐dependent synaptogenesis and dendritic branch‐
ing [126, 134], that are both altered in neurodevelopmental disorders and are thought to be 
important in etiology of schizophrenia and ASD [135].
Actually, MIA changes dramatically neuronal levels of MHCI, in brain of neonatal offspring 
[126], but it is still unknown whether these changes are long‐lasting and related to the behav‐
ior changes related to disease in later stages of development. Alterations in the MHCI levels 
may be acute and directly reflecting the nature, intensity and duration of infection, that can 
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Figure 1. Main changes observed in neuropsychiatric diseases. On left, major immune changes related to schizophrenia 
and autism spectrum diseases (ASD) observed in central nervous system (CNS). A direct interchange is observed from 
cellular and molecular components of peripheral system and CNS due to blood brain barrier (BBB) disruption leading 
to an increase in macrophage infiltration, in microglia activation, and in astrocyte reactivity. There is also an increased 
inflammatory signaling responsible for higher levels of free radicals that together with decreased oligodendrocyte 
numbers favors the myelin damage process [112]. An increase in natural killer (NK) cells can be observed; however, its 
activity is dysfunctional [120]. Altered neurotransmission due to an increased expression of dopaminergic receptors (D1/
D2) [111] and a decrease in N‐methyl‐d‐aspartate (NMDA) receptors expression can be found in part as a consequence 
of the presence of anti‐brain antibodies that among other cerebral targets can recognize NMDA receptors [11]. AMPA 
activity is also disrupted [132]. In peripheral system, a decrease in the shift Th1/Th2 is observed in schizophrenia, 
whereas an increase in Th1/Th2 relation is observed in autism spectrum disorders (ASDs) [11, 115, 120]. Anti‐brain 
antibodies are also detected in peripheral system. On the right, the main changes in inflammatory response in mood 
disorders: bipolar disorder (BD) and major depression disorder (MDD) [38]. Most of the changes are consequence of 
traumas during childhood and/or infections during the development [39]. These diseases have important inflammatory 
markers such as microglia activation [57, 58], HPA (hypothalamic‐pituitary‐adrenal) axis impaired [43, 61, 65] and 
increase in pro‐inflammatory cytokines which are related to each other [72, 75, 89]. The increase of C‐reactive protein 
(CRP) and pro‐inflammatory cytokines could lead to an increase in cortisol levels and also in the BBB disruption that 
could also lead to microglia activation. Since TNF‐α levels are elevated, there is also a modulation of sTNFR1 in BD 
[55]. The chronic high levels of cortisol decrease the GR expression, which contributes to the inflammatory imbalance. 
High levels of cytokines also modulate the amount of neurotransmitters in the synaptic cleft. The levels of noradrenaline 
(NA), dopamine (DA), and serotonin (5‐HT) are downregulated that conducts to the mood changes [85]. TLR4 and TLR2 
pathways are also changed in BD [70, 71], for instance, the MyD88 is increased [59]. The presence of auto‐antibodies is 
also an important feature in BD and MDD, especially anti‐NMDA antibody that impairs glutamatergic pathway and 
could lead to cognitive impairment [51].
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become chronic, due to epigenetic changes that might synergize with other risk factors at dif‐
ferent stages of life. Furthermore, as a convergent signaling pathway to cytokines, synaptic 
scaffolding proteins, and trophic factors, the literature now is trying to understand the role 
of mammalian target of rapamycin (mTOR) signaling pathway in individuals with schizo‐
phrenia, ASD and MIA offspring, as well as schizophrenia‐associated DISC‐1 mutation in 
animal models. Changes in physiological mTOR signaling can implicate in neuronal mor‐
phology changes, as well as synaptic plasticity and synaptic protein and glutamate receptor 
synthesis [113].
Several phenotypes related to schizophrenia and ASD, in MIA offspring, can also be pre‐
vented with probiotics, environmental enrichment, or maternal supplementation with zinc, 
several phenotypes related to schizophrenia and ASD, in MIA offspring, can also be pre‐
vented with probiotics, environmental enrichment, or maternal supplementation with zinc, 
specific antibodies to cytokines [122] and later during adolescence MIA rats treated with 
COX2 inhibitor were protected to develop several schizophrenic behavior aberrations, as 
well as the treatment with minocycline (a microglia modulator) during a stress condition in 
adolescence could prevent adult offspring to develop schizophrenic behavior [125, 127]. In 
particular, autism shares many significant similarities with schizophrenia, including genetic 
variants and neuroinflammation in early development and chronic inflammatory process 
affecting especially pregnant woman [111, 120] leading to aberrant neuronal connectivity, 
synaptic plasticity, and altered neurotransmission in both. Indeed, defects in inhibitory 
(GABAergic) and excitatory (glutamatergic, dopaminergic) neurotransmission leading to 
an imbalance of inhibition/excitation can be found in ASD and schizophrenia [111]. A sum‐
mary of the most relevant similarities between ASD and schizophrenia concerning neuro‐
inflammation in CNS as well as bipolar disorders and major depression are illustrated in 
Figure 1. However, in the immune system some differences can be observed between ASD 
and schizophrenia.
10. Conclusion
Therefore, a better comprehension about the pathophysiology of inflammation and immune 
system especially during fetal and neonatal brain development in psychiatric disorders 
remains an exciting field in science. The hypothesis of finding some answers that lead to 
a potentially preventable or treatable neurodevelopmental disorders is welcome in a field 
where current therapeutics are far from an ideal outcome.
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